We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-11.53%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$361M
AUM Growth
+$175M
Cap. Flow
-$2.52M
Cap. Flow %
-0.7%
Top 10 Hldgs %
90.77%
Holding
111
New
18
Increased
19
Reduced
27
Closed
38

Top Buys

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$5.25M
2
TRAW icon
Traws Pharma
TRAW
+$3.96M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$1.9M
4
BPTH
Bio-Path Holdings Inc
BPTH
+$1.16M
5
TOPS icon
TOP Ships
TOPS
+$1.13M

Top Sells

Rank Stock Value
1
TEUM
Pareteum Corporation
TEUM
+$2.9M
2
RDGT
Ridgetech Inc
RDGT
+$1.59M
3
CRMD icon
CorMedix
CRMD
+$1.59M
4
ARCT icon
Arcturus Therapeutics
ARCT
+$1.28M
5
ATNM icon
Actinium Pharmaceuticals
ATNM
+$1.27M

Sector Composition

Rank Sector Weight
1 Miscellaneous 94.27%
2 Healthcare 5.45%
3 Industrials 0.18%
4 Technology 0.07%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLUR icon
26
PUT
Pluri
PLUR
$14.4M
$708K 0.2%
225
+203
+923% +$5.82K
AVEO
27
PUT
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$673K 0.19%
1,085
+495
+84% +$3.64K
TOPS icon
28
TOP Ships
TOPS
$4.45M
$639K 0.18%
133
+99
+291% +$1.13M
BNTC icon
29
Benitec Biopharma
BNTC
$380M
$603K 0.17%
4,639
-716
-13% -$108K
AUPH icon
30
CALL
Aurinia Pharmaceuticals
AUPH
$2.15B
$590K 0.16%
291
-1,386
-83% -$12.8K
PHAS
31
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$576K 0.16%
94,351
-30,437
-24% -$125K
AMRN
32
Amarin Corp
AMRN
$294M
$575K 0.16%
1,341
-209
-13% -$79.4K
CNSY
33
Cerenome
CNSY
$16.1M
$562K 0.16%
624
+321
+106% +$294K
NMTR
34
DELISTED
9 Meters Biopharma
NMTR
$525K 0.15%
47,079
-15,362
-25% -$256K
CRVO icon
35
CervoMed
CRVO
$37M
$500K 0.14%
14,473
+8,235
+132% +$503K
GHSI
36
DELISTED
Guardion Health Sciences, Inc. Common Stock
GHSI
$439K 0.12%
+6,646
New +$635K
PULM icon
37
Pulmatrix
PULM
$5.3M
$384K 0.11%
22,337
-30,597
-58% -$485K
XBIO icon
38
Xenetic Biosciences
XBIO
$10M
$382K 0.11%
26,550
-13,905
-34% -$177K
PALI icon
39
Palisade Bio
PALI
$352M
$378K 0.1%
85
+39
+85% +$195K
TOVX icon
40
Theriva Biologics
TOVX
$10.3M
$348K 0.1%
2,749
-593
-18% -$63.1K
XBIOW
41
DELISTED
Xenetic Biosciences, Inc. Warrants
XBIOW
$297K 0.08%
216,789
-50,000
-19% -$65.7K
AIM
42
AIM ImmunoTech
AIM
$7.99M
$288K 0.08%
5,293
+3,439
+185% +$173K
CYTO
43
DELISTED
Altamira Therapeutics Ltd
CYTO
$278K 0.08%
430
+11
+3% +$7.46K
NURO
44
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$275K 0.08%
7,985
-3,693
-32% -$107K
LFWD icon
45
ReWalk Robotics
LFWD
$20M
$273K 0.08%
1,503
+134
+10% +$29.1K
NSPR icon
46
InspireMD
NSPR
$36.1M
$270K 0.07%
16,667
-4,238
-20% -$67.1K
OTLK icon
47
Outlook Therapeutics
OTLK
$164M
$229K 0.06%
+19,447
New +$453K
AVEO
48
CALL
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$225K 0.06%
+363
New +$2.67K
PLUR icon
49
Pluri
PLUR
$14.4M
$222K 0.06%
7,055
+2,406
+52% +$69K
ABEO icon
50
Abeona Therapeutics
ABEO
$313M
$197K 0.05%
+2,414
New +$170K
1
2
3 4 5

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2019 Portfolio in Review

As of Q4 2019, Sabby Management held 111 positions worth $361M, up 94% from $186M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Sabby Management's Q4 2019 filing shows 18 new, 19 increased, 27 reduced and 38 closed positions. Its largest new stake was SPDR Gold Trust: 37,550 shares worth $5.37M. The largest sale was Pareteum Corporation, an estimated $2.9M.

By sector, the portfolio is most concentrated in Miscellaneous at 94% of assets, up from 82% a quarter earlier, followed by Healthcare and Industrials.

  • Sabby Management's largest Q4 2019 buy was SPDR Gold Trust: 37,550 shares worth $5.37M.
  • Sabby Management added most to Traws Pharma in Q4 2019, an estimated $3.96M increase.
  • Sabby Management's biggest Q4 2019 reduction was Actinium Pharmaceuticals, cutting an estimated $1.27M.
  • Sabby Management fully exited Pareteum Corporation in Q4 2019, selling an estimated $2.9M.
  • Sabby Management's ten largest holdings make up 91% of its $361M portfolio in Q4 2019.
  • Sabby Management opened 18 new positions and closed 38 in Q4 2019.
  • Sabby Management's portfolio value rose 94% quarter-over-quarter to $361M.

Based on Sabby Management's 13F filing for Q4 2019, filed 14 Feb 2020.